Jan 21, 2025 08:03AM
Jan 21, 2025 08:00AM
Nov 7, 2024 04:05PM
Aug 8, 2024 04:05PM
May 9, 2024 04:07PM
May 9, 2024 04:05PM
Apr 12, 2024 08:00AM Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Feb 28, 2024 04:05PM
Feb 2, 2024 08:00AM
Jan 8, 2024 08:15AM
Jan 8, 2024 08:00AM
Nov 8, 2023 04:06PM
Oct 26, 2023 08:00AM
Aug 14, 2023 08:00AM Revance Therapeutics (RVNC) Announces FDA Approves First Therapeutic Indication for DAXXIFY for Injection for the Treatment of Cervical Dystonia
Aug 14, 2023 08:00AM
Aug 8, 2023 04:05PM
May 9, 2023 04:05PM
Mar 30, 2023 08:00AM
Feb 28, 2023 04:06PM
Feb 23, 2023 08:00AM
Jan 9, 2023 08:00AM Revance Therapeutics (RVNC) Provides an Update on DAXXIFY Launch, Reports Prelim Q4 Results
Jan 9, 2023 08:00AM
Jan 9, 2023 05:11AM
Jan 6, 2023 06:00PM
Nov 8, 2022 04:05PM
Nov 4, 2022 08:00AM
Oct 20, 2022 08:02AM
Oct 20, 2022 08:00AM Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Oct 17, 2022 08:05AM
Oct 17, 2022 08:00AM
Oct 10, 2022 08:00AM
Sep 19, 2022 08:00AM
Sep 19, 2022 08:00AM
Sep 8, 2022 11:19AM
Sep 8, 2022 10:44AM Revance Therapeutic (RVNC) PT Raised to $65 at Cowen After Daxxify Approved
Sep 8, 2022 10:28AM
Sep 8, 2022 07:03AM
Sep 8, 2022 07:00AM
Aug 9, 2022 04:05PM
Aug 2, 2022 04:05PM
Jul 27, 2022 08:00AM
May 23, 2022 08:00AM Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 12, 2022 06:24AM
May 10, 2022 04:05PM
May 3, 2022 08:00AM
Apr 21, 2022 04:06PM
Apr 21, 2022 04:05PM
Mar 28, 2022 08:00AM
Mar 28, 2022 08:00AM Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting
Mar 22, 2022 06:28AM

322,092 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All